Skip to main content
. 2021 Jul 22;15(12):3430–3446. doi: 10.1002/1878-0261.13052

Fig. 5.

Fig. 5

Improved efficacy of siCPT1A delivered by iRGD‐exos in colon cancer. (A–B) Expression of CPT1A in colon cancer cell lines after coculture with iRGD/control‐exo‐si by western blotting (A) and qRT‐PCR (B) (n = 3, mean ± SEM, t‐test). (C)Evaluation of the rate of proliferating cells after coculture with iRGD/control‐exo‐si or oxaliplatin by EdU assay (scale bar = 50 μm, n = 3, mean ± SEM, t‐test). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.